Benefits of once-daily therapies in the treatment of hypertension

被引:40
|
作者
Flack, John M. [1 ,2 ,3 ]
Nasser, Samar A. [1 ,2 ,3 ]
机构
[1] Wayne State Univ, Sch Med, Dept Internal Med, Div Translat Res, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Internal Med, Div Clin Epidemiol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Internal Med, Div Endocrinol, Detroit, MI 48201 USA
基金
美国国家卫生研究院;
关键词
adherence; blood pressure control; therapeutic coverage;
D O I
10.2147/VHRM.S17207
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In patients with hypertension, 24-hour blood pressure control is the major therapeutic goal. The number of daily doses is one characteristic of an antihypertensive agent that may affect the adequacy of 24-hour control. One measure of therapeutic coverage is the 24-hour trough-to-peak ratio, which determines the suitability of an agent for once-daily administration. The closer an agent is to a 100% trough-to-peak ratio, the more uniform the 24-hour coverage and therefore blood pressure control. High trough-to-peak ratio, long-acting antihypertensive medications lower blood pressure more gradually, which reduces the likelihood of adverse events attributable to abrupt drug action that occurs with shorter-acting agents. In hypertension, the natural diurnal variation of blood pressure may be altered, including elevated nighttime -pressures. An optimal once-daily hypertension therapy would not only lower blood pressure but also normalize any blunted circadian variations in blood pressure. The benefits of once-daily agents with sustained therapeutic coverage may also be explained, in part, by increased patient adherence to simpler regimens as well as lower loss of blood pressure control during virtually inevitable intermittent noncompliance. Studies have demonstrated that once-daily antihypertensive agents have the highest adherence compared with twice-daily or multiple daily doses, including greater adherence to the prescribed timing of doses.
引用
收藏
页码:777 / 787
页数:11
相关论文
共 50 条
  • [41] PILOT-STUDY OF ONCE-DAILY PENBUTOLOL IN HYPERTENSION
    SAINANI, GS
    SHAH, GM
    NANDI, JS
    GULATI, RB
    PHARMATHERAPEUTICA, 1977, 1 (08) : 493 - 497
  • [42] EFFICACY OF ONCE-DAILY LISINOPRIL MONOTHERAPY IN SYSTEMIC HYPERTENSION
    HWANG, YS
    YEN, HW
    CLINICAL CARDIOLOGY, 1993, 16 (02) : 129 - 132
  • [43] SAFETY AND EFFICACY OF ONCE-DAILY DOSING OF PROPRANOLOL FOR HYPERTENSION
    LOPEZ, LM
    GEFTER, ML
    HEMMES, RJ
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1982, 16 (06): : 476 - 476
  • [44] ORAL BETAXOLOL APPROVED FOR ONCE-DAILY THERAPY OF HYPERTENSION
    不详
    CLINICAL PHARMACY, 1990, 9 (02): : 87 - 89
  • [45] EFFICACY OF ONCE-DAILY FELODIPINE MONOTHERAPY IN SYSTEMIC HYPERTENSION
    HWANG, YS
    YEN, HW
    WONG, ECK
    AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (03): : 271 - 274
  • [46] GLAUCOMA TREATMENT WITH ONCE-DAILY LEVOBUNOLOL - REPLY
    WANDEL, T
    CHARAP, A
    LEWIS, RA
    PARTAMIAN, L
    COBB, S
    LUE, J
    NOVACK, GD
    GASTER, R
    SMITH, J
    DUZMAN, E
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 102 (04) : 546 - 547
  • [47] ONCE-DAILY THEOPHYLLINE IN THE TREATMENT OF NOCTURNAL ASTHMA
    VILKKA, V
    BRANDER, P
    HAKULINEN, A
    LAITINEN, J
    SAHLSTROM, K
    AALTO, E
    SILVASTI, M
    KARTTUNEN, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (03) : 241 - 243
  • [48] Tolterodine once-daily in treatment of the overactive bladder
    Appell, RA
    Anderson, R
    Diokno, AC
    Dmochowski, R
    Staskin, D
    UROLOGY, 2001, 58 (05) : 830 - 831
  • [49] Once-daily topical treatment for psoriasis: calcipotriene
    Shepherd, Jonisha
    Taheri, Arash
    Feldman, Steven R.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2014, 7 : 19 - 22
  • [50] Treatment of HIV infection with once-daily regimens
    Permpalung, Nitipong
    Putcharoen, Opass
    Avihingsanon, Anchalee
    Ruxrungtham, Kiat
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2301 - 2317